Comparison of gastrointestinal tolerability and patient preference for treatment with the 625 mg and 250 mg nelfinavir tablet formulations

HIV Medicine

Volumn 6, Issue 2, 2005, Pages 107-113

  Johnson, Margaret ^a   Nieto Cisneros, L ^b   Horban, A ^c   Arasteh, K ^d   Gonzalez Garcia, J ^e   Artigas, J G ^f   Clotet, B ^g   Danise, A ^h   Landman, R ⁱ   Proll, S ^j   Snowden, W ^j   Foreman, R ^j   Smith, P ^k  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c Wojewodzki Szpital Zokozny   (Poland)

^d Vivantes Auguste Viktoria Klinikum   (Germany)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^h SAN RAFFAELE HOSPITAL   (Italy)

ⁱ BICHAT HOSPITAL   (France)

^j ROCHE PRODUCTS LTD   (United Kingdom)

^k Statistics for Research SFR Ltd   (Switzerland)

more..

Author keywords

Diarrhoea; HIV; Nelfinavir 625 mg; Tolerability

Indexed keywords

NELFINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG MARKETING; DRUG PREFERENCE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FEMALE; FREQUENCY ANALYSIS; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTICENTER STUDY; NAUSEA; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; TABLET FORMULATION;

CD4 LYMPHOCYTE COUNT; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; NELFINAVIR; PATIENT SATISFACTION; TABLETS; VIRAL LOAD;

EID: 20144372231     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00272.x     Document Type: Article

References (21)

1. Saag MS, Tebas P, Sension M et al. Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511). AIDS 2001; 15: 1971 1978.
2. Petersen A, Antunes F, Arasteh KN et al. A comparison of the long-term antiviral efficacy of BID and TID dosing of nelfinavir in combination with stavudine (d4T) and lamivudine (3TC) beyond 48 weeks. 7th European Conference on Clinical Aspects and Treatment of HIV Infection. Lisbon, October 2000 [Abstract 205].
3. Gathe J, Chu A, Yuen N, Petersen A. Durability of nelfinavir combination therapy after 4 years: 3-year extension data from Agouron Study 511. 8th European Conference on Clinical Aspects and Treatment of HIV Infection. Athens, October 2001 [Abstract LB 10).
4. Murpby RL, Sanne I, Cahn P et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naïve subjects: 48-week results. AIDS 2003; 17 2603 2614.
5. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S and AI424-007 Clinical Trial Group. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003; 32: 18 29.
6. Schürmann D, Gathe J, Sanne I, Wood R. Efficacy and safety of GW433908/RTV once daily in therapy naïve subjects (the SOLO study): 48 week results. 6th International Congress on Drug Therapy in HIV Infection. Glasgow, November 20002 [Abstract PL14.4].
7. Proctor VE, Tesfa A, Tompkins DC. Barriers to adherence to highly active antiretroviral therapy as expressed by people living with HIV/AIDS. AIDS Patient Care STDs 1999; 13: 535 544.
8. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001; 15: 1369 1377.
9. Charoin J-E, Oxley P, Gerber M, Saiedabadi N, Kaeser B. Pharmacokinetics of Roche nelfinavir 625mg film-coated tablets and nelfinavir 250mg film-coated (Viracept) are comparable. 4th International Workshop on Clinical Pharmacology of HIV Therapy. Cannes, 2003 [Abstract 6.5].
10. Hall CS, Raines CP, Barnett SH, Moore RD, Gallant JE. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens. AIDS 1999; 13: 1207 1212.
11. Zolopa AR, Shafer RW, Warford A et al. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med 1999; 131: 813 821.
12. Tebas P, Patick AK, Kane EM et al. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS 1999; 13: F23 F28.
13. Perez-Rodriguez E, Gonzalez L, Kopp B, The role of calcium supplements in the treatment of nelfinavir-induced diarrhea. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1999 [Abstract 1308]..
14. Pun E, Daniels E, Petersen C, Mota J. Nelfinavir associated diarrhea: incidence, time course and treatment. International Workshop on Management of Treatment-Experienced Patients. San Diego, September 2002 [Abstract 119].
15. Negredo E, Sirera G, Puig J, Fumaz C, Gel S, Clotet B. Management of nelfinavir-related diarrhoea. 14th World AIDS Conference Barcelona, July 2002 [Abstract TuPeB4526).
16. Roche Registration Ltd. Viracept® (Nelfinavir Mesylate:) Summary of Product Characteristics. Roche Registration Ltd.: Welwyn Garden City, UK 2003.
17. Kaesar B, Akintola D-J, Saifulanwar A, Boyce M, Smith P. Improved gastrointestinal tolerability of Roche nelfinavir 625 mg film-coated tablets in comparison with nelfinavir 250 mg film-coated tablets (Viracept). 4th International Workshop on Clinical Pharmacology of HIV Therapy. Cannes, March 2003 [Abstract, 6.4].
18. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32: 920 924.
19. AIDS Clinical Trials Group. Table of Grading Severity of Adult Adverse Experiences. Rockville, National Institute of Allergy and Infectious Diseases, 1996.
20. O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003; 34: 407 414.
21. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21 30.